THE ONLY WAY IS UP – OR IS IT?

MEDTECH AT THE END OF H1

M&A

The other shoe finally drops for device dealmaking.

<table>
<thead>
<tr>
<th>H1 2022</th>
<th>H1 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Deals</td>
<td>38</td>
</tr>
<tr>
<td>Total Deal Value</td>
<td>$21 bn</td>
</tr>
<tr>
<td>Biggest Deal</td>
<td>$6 bn</td>
</tr>
<tr>
<td>Average Deal Size</td>
<td>$828m</td>
</tr>
</tbody>
</table>

VENTURE FINANCING & IPOs

VCs are still backing medtechs in a big way, but the climate for flotations is poor.

<table>
<thead>
<tr>
<th>VC INVESTMENT</th>
<th>IPOs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deals</td>
<td>91</td>
</tr>
<tr>
<td>Total Deal Value</td>
<td>$4.4bn</td>
</tr>
</tbody>
</table>

Covid & market gloom results in the fewest acquisitions for over 20 years.

2022 looks set to see the fewest new devices since 2013.*

* At current rates, devices hitting the US market.

H1 SHARE PRICE PERFORMANCE

The nightmare on the public markets continues.

GOING UP

+60% BONESUPPORT

+38% NATUR MEDICAL

+23% HAEMONETICS

+3% OLMPUS

GOING DOWN

-84% INVITAE

-64% ALIGN TECHNOLOGY

-64% TELEDOC HEALTH

-47% SYSMEX

Don't Miss Out on our Full Q2 Report

Evaluate Vantage | Biopharma, Biotech and Medtech in Q2: The only way is up... or is it?

BY AMY BROWN, EDWIN ELMHIRST, ELIZABETH CAIRNS, JACOB PLIETH AND MADELEINE ARMSTRONG | JULY 2022

© 2022 Evaluate Ltd. All rights reserved.

Evaluate Vantage | Biopharma, Biotech and Medtech in Q2: The only way is up... or is it?

The nightmare on the public markets continues.

M&A

The other shoe finally drops for device dealmaking.

<table>
<thead>
<tr>
<th>H1 2022</th>
<th>H1 2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Deals</td>
<td>38</td>
</tr>
<tr>
<td>Total Deal Value</td>
<td>$21 bn</td>
</tr>
<tr>
<td>Biggest Deal</td>
<td>$6 bn</td>
</tr>
<tr>
<td>Average Deal Size</td>
<td>$828m</td>
</tr>
</tbody>
</table>

VENTURE FINANCING & IPOs

VCs are still backing medtechs in a big way, but the climate for flotations is poor.

<table>
<thead>
<tr>
<th>VC INVESTMENT</th>
<th>IPOs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deals</td>
<td>91</td>
</tr>
<tr>
<td>Total Deal Value</td>
<td>$4.4bn</td>
</tr>
</tbody>
</table>

Covid & market gloom results in the fewest acquisitions for over 20 years.

2022 looks set to see the fewest new devices since 2013.*

* At current rates, devices hitting the US market.

H1 SHARE PRICE PERFORMANCE

The nightmare on the public markets continues.

GOING UP

+60% BONESUPPORT

+38% NATUR MEDICAL

+23% HAEMONETICS

+3% OLMPUS

GOING DOWN

-84% INVITAE

-64% ALIGN TECHNOLOGY

-64% TELEDOC HEALTH

-47% SYSMEX

Don’t Miss Out on our Full Q2 Report

Evaluate Vantage | Biopharma, Biotech and Medtech in Q2: The only way is up... or is it?

BY AMY BROWN, EDWIN ELMHIRST, ELIZABETH CAIRNS, JACOB PLIETH AND MADELEINE ARMSTRONG | JULY 2022

© 2022 Evaluate Ltd. All rights reserved.